News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Renal Solutions Announces Medical Advisory Board


7/18/2006 10:59:50 AM

WARRENDALE, Pa., July 18 /PRNewswire/ -- Renal Solutions, Inc., the exclusive provider of advanced sorbent hemodialysis products and services for treatment of patients with renal failure, today announces the formation of its Medical Advisory Board. This team of key nephrology thought leaders provides diverse experience in clinical, academic, and private practice settings in both national and international settings. The Board will provide strategic advice to Renal Solutions in the areas of medical issues, clinical use studies, product development, and market introduction.

"We are pleased to have this Board of renowned experts assist Renal Solutions in the strategic development of its products and services," said Peter M. DeComo, Chairman and CEO of Renal Solutions. "We are honored that this core group of accomplished nephrologists has agreed to join us in addressing important quality-of-care issues and anticipate the addition of a few key members over time," DeComo added.

Derrick L. Latos, MD, MACP, has been appointed Chairman of the Medical Advisory Board and serves as Medical Director of Renal Solutions. Dr. Latos is a Clinical Professor of Medicine at the West Virginia University School of Medicine and Medical Director for Wheeling Renal Care, LLC. in Wheeling, W.V. He is past president of the Forum of ESRD Networks and of the Renal Physicians Association. He also serves on the Editorial Advisory Board of Nephrology News and Issues and on the Board of the National Kidney Foundation of Western Pennsylvania.

"I am delighted to be involved in the strategic guidance of such an innovative company," Dr. Latos stated. "The Renal Solutions team is extremely dedicated to innovations in treatment of renal failure toward the goal of improved quality of life for patients -- and has shown this determination through the development and continued improvement of excellent products and services."

Additional Renal Solutions Medical Advisory Board members include the following:

John Agar, MBBS, FRCP(Lond), FRACP, a renowned nocturnal home hemodialysis advocate, is Director of Nephrology and Chief of Service Medicine at Barwon Health in Geelong, Australia. Currently, he is the senior transplant physician to the Transplant Service at St. Vincent's Hospital, Melbourne, and is a Clinical Associate Professor of Medicine at the University of Melbourne. An enthusiastic home hemodialysis supporter, 40% of his dialysis patient population dialyzes at home with 25% of his hemodialysis patients using nocturnal home hemodialysis. Dr. Agar has been widely published in peer- reviewed literature on the medical and economic benefits of nocturnal home hemodialysis and has been a recognized leader in the expansion of this innovative therapy in Australia.

Stephen R. Ash, MD, FACP. brings extensive experience in the fields of sorbent based dialysis systems, peritoneal and hemodialysis to the Board. Dr. Ash is co-inventor of the Allient(R) Sorbent Hemodialysis System and co- founder of Renal Solutions. He serves as Chairman of the Board of HemoCleanse, Inc. and Ash Access Technology, Inc. Dr. Ash is also Director of the Dialysis Center for Greater Lafayette and a practicing Nephrologist at Arnett Clinic in Lafayette, Indiana. He has been awarded over 30 patents for various dialysis devices and therapeutic instruments, has published over 100 peer-reviewed articles, and is author of 12 textbook chapters regarding hemodialysis and peritoneal dialysis.

Robert S. Lockridge Jr., M.D. is a highly acclaimed innovator in the efforts to provide more frequent, long-duration dialysis in the United States. Dr. Lockridge is Medical Director of UVA-Lynchburg Dialysis Facility and a partner of Lynchburg Nephrology Physicians in Lynchburg, VA, widely recognized as one of the leading and most successful nocturnal home hemodialysis programs, founded in 1997. Dr. Lockridge is a leader in advocacy initiatives, having played an instrumental role in the introduction and lobbying of legislation supporting enhanced home dialysis reimbursement and is active in the National Institutes of Health (NIH) study on long duration home hemodialysis. He also serves as a Clinical Associate Professor of Internal Medicine at the University of Virginia School Health System.

About Renal Solutions, Inc.

http://www.renalsolutionsinc.com

Renal Solutions, Inc. is a medical device firm and the leader in innovative, sorbent-based hemodialysis solutions and services that maximize patient outcomes and quality of life. Renal Solutions develops, manufacturers and distributes the most convenient and flexible treatment options, resulting in high quality therapy and outcomes for a virtually unlimited range of treatment environments. The company's lead product, the Allient(R) Sorbent Hemodialysis System, opens new treatment options by virtue of its ability to provide wide flexibility in therapy duration using just 1 & 1/2 gallons of ordinary drinking water. The Allient System provides the increased dose advantage without the need for large volumes of sterile fluids or an independent water system. This translates into increased transportability, flexibility and ease of system use.

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company's control. Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement for the Company's products/services and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward- looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

Renal Solutions, Inc.

CONTACT: Media Inquiries: Jennifer Bannan of Zero to Five,+1-412-580-3675, jen@0to5.com, for Renal Solutions; or Commercial Inquires:Sue Bentley, Marketing Director, Renal Solutions, +1-724-772-6900 ext. 109,sue.bentley@renalsolutionsinc.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES